ClinicalTrials.gg
CompletedNCT01562587Updated Jan 12, 2017

Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State

A Phase 1 interventional study of activated recombinant human factor VII and activated recombinant human factor VII in Congenital Bleeding Disorder, Haemophilia A and Haemophilia B, sponsored by Novo Nordisk A/S. Completed at 8 sites in 5 countries. Open to male participants aged 3 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
3 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
12th of 19
18 · median 24
Started
2002
with 1 other
Phase 1
7 of 20
none open now
Registered
12th of 20
by date
Lead sponsor
11 of 20
Novo Nordisk A/S

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2002, is one of 7 in phase 1, and was the 12th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 3 Years to 55 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to determine the pharmacokinetics of activated recombinant human factor VII (NovoSeven®) in haemophiliac patients in a non-bleeding state.

03

Conditions studied

  • Congenital Bleeding Disorder
  • Haemophilia A
  • Haemophilia B
04

Who can participate

Ages eligible
3 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-55 years and congenital haemophilia A or B male with severe FVIII or FX deficiency +/-inhibitors
  • Age between 3-12 years and congenital haemophilia A or B male with record of inhibitors

Exclusion criteria

Exclusion Criteria:

  • Known to activated recombinant human factor VII or any of its components
  • Known clinical relevant coagulation diseases or insufficiencies other than congenital haemophilia
  • Clinical manifestation of (human immunodeficiency virus) and/or protease inhibitor treatment
  • Clinical manifestation of active/recent bleeding
  • Administration of coagulation factor preparations within 24 hours of NovoSeven trial product dose administration
  • (BMI) outside normal range
  • Known abuse of elicit drugs and/or alcohol
  • Renal insufficiency
  • Hepatic disease
  • Cardiovascular disease
  • Any disease or condition which, judged by the Investigator, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Adults

    Drug: activated recombinant human factor VII

  • Experimental
    Paediatric

    Drug: activated recombinant human factor VII

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration curve from 0-12 hours

Secondary outcomes

  1. CL, the total body clearance

  2. Cmax, the maximum concentration

  3. tmax, the time to maximum concentration

  4. t1/2, the terminal half-life

  5. Area under the concentration curve from time 0-infinity

  6. Vss, the apparent volume of distribution at steady state

  7. Adverse events

07

Study locations

8 sites
  • Novo Nordisk Investigational Site
    Bremen, 28205, Germany
  • Novo Nordisk Investigational Site
    Frankfurt, 60590, Germany
  • Novo Nordisk Investigational Site
    Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Firenze, 50134, Italy
  • Novo Nordisk Investigational Site
    Milano, 20124, Italy
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    London, WC1N 3JH, United Kingdom
  • Novo Nordisk Investigational Site
    Oxford, OX3 7LJ, United Kingdom
08

References and documents

Publications

  • Villar A, Aronis S, Morfini M, Santagostino E, Auerswald G, Thomsen HF, Erhardtsen E, Giangrande PL. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia. 2004 Jul;10(4):352-9. doi: 10.1111/j.1365-2516.2004.00925.x. PubMed 15230949 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2002, a primary completion of May 2003 and a completion of May 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2012
First posted
Mar 26, 2012
Start
Sep 2002
Primary completionActual
May 2003
CompletionActual
May 2003
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01562587
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 26, 2012
Start date
Sep 2002
Primary completion
May 2003
Completion
May 2003
Last update
Jan 12, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion